Immunoprecise SEC Filings

HNI Corporation (HNI) delivered a stronger second-quarter FY 2025. Net sales climbed 7% year-on-year to $667.1 million, led by 7.4% growth in Workplace Furnishings and 5.3% in Residential Building Products. Gross margin expanded 100 bp to 42.9% and operating margin improved 160 bp to 10.2%, lifting operating income 28% to $68.2 million.

Net income attributable to shareholders rose 34% to $48.2 million ($1.02 diluted EPS, +36%). For 1H 2025, revenue increased 4.6% to $1.27 billion while diluted EPS advanced 18% to $1.31.

Operating cash flow was $43.7 million (-7% YoY). The company spent $79.8 million repurchasing 1.7 million shares and invested $31.2 million in capex. Long-term debt reached $444.4 million (vs. $344.6 million at FY-24) as revolver borrowings rose to $195.6 million; cash ended at $32.0 million. Interest expense decreased to $6.1 million on lower average rates and balances.

During the quarter HNI divested its HNI India unit, booking a $6.4 million pre-tax loss within restructuring and divestiture costs. The board raised the quarterly dividend 3% to $0.34 per share. Management continues to pursue margin-expansion initiatives, Kimball International integration synergies, and factory optimization.

Ramaco Resources, Inc. (Nasdaq: METC/METCB; Notes: METCL, METCZ) filed a Form 8-K dated 29 Jul 2025 to disclose that the Wyoming Department of Environmental Quality’s Land Quality Division granted the company a second five-year permit for its Brook Mine project. The approval, announced through an attached press release (Exhibit 99.1), is reported under Item 8.01 — Other Events.

No financial statements, earnings data, or transaction details are included. The filing solely communicates the regulatory milestone, which removes a key permitting hurdle for future mine development. There are no additional material events or changes reported.

AllianceBernstein Holding L.P. (NYSE: AB) – Schedule 13D/A Amendment No. 36 (dated 10 July 2025)

The filing discloses an Amended & Restated Master Exchange Agreement between AllianceBernstein L.P. ("AB") and Equitable Holdings, Inc. ("EQH") and its wholly-owned subsidiaries Alpha Units Holdings, Inc. and Alpha Units Holdings II, Inc.

• Issuance & Exchange: AB issued 19,682,946 new AB Units to EQH and its subsidiaries in exchange for an equal number of AB Holding Units, which were immediately retired.
• Post-transaction ownership:
  • EQH – 81,445,154 AB Units (27.87% of units outstanding)
  • Alpha Units Holdings – 75,851,289 units (25.95%)
  • Alpha Units Holdings II – 41,934,582 units (14.34%)
  • Combined indirect control via Equitable Holdings totals 199,231,025 units, or 68.17% of all AB Units outstanding.
• Purpose: The amendment updates Items 3, 4 and 5 of the original 13D to reflect the exchange and current ownership. No additional strategic plans or proposals under Items 4(a)-(j) are reported.
• Transaction window: Other than the exchange described, the reporting persons executed no transactions in the past 60 days.

The filing is administrative in nature, clarifying capital-structure changes and reaffirming EQH’s majority economic interest in AB.

Bank of America Corporation (BAC), through its subsidiary BofA Finance LLC, is marketing Autocallable Leveraged Index Return Notes (LIRNs) linked to the S&P SmallCap 600 Index ("SML").

Key commercial terms:

• Denomination: $10 per unit; no exchange listing planned.
• Term: ≈3 years unless automatically called after ≈1 year.
• Automatic Call: Notes are redeemed early at $11.125–$11.225 (≈11.2% premium) if the SML closes ≥ Starting Value on the single Observation Date.
• Upside Participation: If held to maturity and not called, investors receive 150% of any positive SML return with no cap.
• Downside Exposure: 1-for-1 loss on any decline in the SML; the Threshold Value equals the Starting Value, so there is no downside buffer.
• Interest Payments: None; all return is via call premium or leveraged payoff.
• Credit: Senior unsecured obligations of BofA Finance, fully and unconditionally guaranteed by BAC.

Risk highlights (as disclosed): potential loss of entire principal, issuer/guarantor credit risk, initial price includes underwriting discount (secondary value likely below issue price), small-cap equity volatility, and lack of liquidity due to absent exchange listing.

Investors considering the notes are advised to review the Preliminary Offering Documents for complete terms, tax treatment, and additional risks.

ImmunoPrecise Antibodies filed a Form 6-K (foreign issuer report) on June 28, 2025, indicating the submission of a press release dated June 24, 2025. The filing was signed by Jennifer Bath, who serves as President and Chief Executive Officer.

The company confirms it will file annual reports under Form 20-F rather than Form 40-F. The principal executive office is located in Austin, Texas.

Note: While this is a Form 6-K filing, the actual content and details of the press release (Exhibit 99.1) are not included in this portion of the filing. The Form 6-K serves primarily as a cover document for the attached press release, which would contain the material information being reported to shareholders.